SCHEMBL3398971

SCHEMBL3398971

COP(C)(=O)OCC(C)=O

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
CES2 O00748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10011067 0.79 TSHR (0.40) MGAMGAASIMGAM2
SCHEMBL6991478 0.78 MGAM (0.35) MGAMGAASIMGAM2CES2
SCHEMBL6382382 0.77
SCHEMBL27815438 0.77
SCHEMBL17482402 0.76 PLA2G2A (0.39) MGAMGAASIMGAM2CES2
SCHEMBL11505831 0.74 HCAR2 (0.37)
SCHEMBL11849560 0.74 LMNA (0.35) CES2
SCHEMBL6228266 0.74 TSHR (0.43) MGAMGAASIMGAM2CES2
SCHEMBL25656671 0.73
SCHEMBL14017058 0.73 ALDH1A1 (0.37) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60258194-A None JP disclosed
US-20150299090-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2015-10-22 US disclosed
EP-2684861-A2 Spiro compounds and pharmaceutical use thereof Japan Tobacco Inc. (JP) 2014-01-15 EP disclosed
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2013-05-02 US disclosed
US-8299296-B2 Spiro compounds and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2012-10-30 US disclosed
EP-2508503-A1 Spiro compounds and pharmaceutical use thereof Japan Tobacco, Inc. (JP) 2012-10-10 EP disclosed
EP-2202216-B1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES JAPAN TOBACCO INC (JP) 2012-06-27 EP disclosed
EP-2202216-A1 SPIRO-RING COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco Inc. (JP) 2010-06-30 EP disclosed
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2009-07-02 US disclosed
US-6552239-B1 Reacting ketophosphonate with diazo-transfer reagent generating a ketodiazophosphonate which is reacted with cyclopropanecarboxaldehyde MERCK & CO., INC. 2003-04-22 US disclosed
EP-0299761-A1 Anti-inflammatory aryl derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1989-01-18 EP disclosed
EP-0107693-B1 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1988-07-27 EP disclosed
US-4638002-A ANTIAGGLOMERANTS, HYPOTENSIVE, ANTISECRETORY, ANTISPASMODIC, ANTIULCER, BRONCHODILATOR, ANTIHISTAMINES CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1987-01-20 US disclosed
JP-S60258194-A DIHYDROPYRIDINE DERIVATIVE OTSUKA PHARMACEUT FACTORY INC 1985-12-20 JP disclosed
US-4520101-A FERMENTATION WITH ADDITION OF PHOSPHORUS COMPOUNDS BRISTOL-MYERS COMPANY (US) 1985-05-28 US disclosed
EP-0107693-A4 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. CHINOIN GYOGYSZER ES VEGYESZET (HU) 1984-09-17 EP disclosed
EP-0107693-A1 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. CHINOIN GYOGYSZER ES VEGYESZET (HU) 1984-05-09 EP disclosed
WO-1983004021-A1 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLINE-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) 1983-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170908-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 MGAM 1285/4885GAA 682/4885SI 101/4885
US-20150299090-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 MGAM 1285/4885GAA 682/4885SI 101/4885
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 MGAM 1285/4885GAA 682/4885SI 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.